Vaccitech, which develops T cell immunotherapies and vaccines for cancers, COVID-19, and other diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company utilizes its proprietary platform to develop a broad pipeline of both clinical and preclinical stage therapeutic and prophylactic programs, including VTP-300 for the treatment of chronic hepatitis B infection, VTP-200 for the treatment of HPV, VTP-850 for the treatment of prostate cancer, and VTP-600 for the treatment of non-small cell lung cancer. Current prophylactic programs include VTP-400 for the prevention of shingles, and VTP-500 for the prevention of Middle East respiratory syndrome. Vaccitech has also co-invented a COVID-19 vaccine candidate with the University of Oxford, which was assigned to Oxford University Innovation, to facilitate the license of those rights by OUI to AstraZeneca.
The Oxford, United Kingdom-based company was founded in 2016 and booked $5 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol VACC. Vaccitech filed confidentially on December 23, 2020. Morgan Stanley, Jefferies, Barclays and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
